Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chimerigen
CD152 [CTLA-4] (mouse):Fc (mouse) (rec.)
Product Details | |
---|---|
Synonyms | CTLA-4 |
Product Type | Protein |
Properties | |
Source/Host | NS1 cells |
Sequence |
The extracellular domain of mouse CD152 [CTLA-4] (aa 38-160) is fused to the N-terminus of the Fc region of mouse IgG2a. |
Crossreactivity | Mouse |
Biological Activity |
Binds both CD80 (B7-1) and CD86 (B7-2) with high affinity and inhibits CD28 signaling competitively. Kills the target cell completely. |
Purity | ≥98% (SDS-PAGE) |
Endotoxin Content | <0.06EU/μg protein (LAL test; Lonza). |
Reconstitution |
Reconstitute at 1mg/ml in sterile water. Add 1X PBS to the desired protein concentration. |
Formulation | Lyophilized from 0.2μm-filtered solution in PBS. |
Protein Negative Control | |
Other Product Data |
NCBI reference NP_033973.2: CD152 (mouse) |
Declaration | Manufactured by Chimerigen. |
Shipping and Handling | |
Shipping | BLUE ICE |
Short Term Storage | +4°C |
Long Term Storage | -20°C |
Handling Advice |
Avoid freeze/thaw cycles. Centrifuge lyophilized vial before opening and reconstitution. |
Use/Stability |
Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C. |
Documents | |
MSDS | Inquire |
Product Specification Sheet | |
Datasheet | Download PDF |
CD152 [CTLA-4] and CD28, together with their ligands B7-1 and B7-2, constitute one of the dominant costimulatory pathways that regulate T and B cell responses. CD152 and CD28 are structurally homologous molecules that are members of the immunoglobulin (Ig) gene superfamily. Both CD152 and CD28 are composed of a single Ig V-like extracellular domain, a transmembrane domain and an intracellular domain. CD152 and CD28 are both expressed on the cell surface as disulfide-linked homodimers or as monomers. CD152 was originally identified as a gene that was specifically expressed by cytotoxic T lymphocytes. However, CD152 transcripts have since been found in both Th1 and Th2, and CD4+ and CD8+ T cell clones. Whereas, CD28 expression is constitutive on the surfaces of 95% of CD4+ T cells and 50% of CD8+ T cells and is down regulated upon T cell activation, CD152 expression is upregulated rapidly following T cell activation and peaks approximately 24 hours following activation. Although both CD152 and CD28 can bind to the same ligands, CD152 binds to B71 and B72 with 20-100-fold higher affinity than CD28.
- Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance: W. Steurer, et al.; J. Immunol. 155, 1165 (1995)
- CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice : E.A. Tivol, et al.; J. Immunol. 158, 5091 (1997)
- Cutting edge: the related molecules CD28 and inducible costimulator deliver both unique and complementary signals required for optimal T cell activation: J.A. Gonzalo, et al.; J. Immunol. 166, 1 (2001)
- Recombinant Adenovirus Coexpressing Covalent Peptide/MHC Class II Complex and B7-1: In Vitro and In Vivo Activation of Myelin Basic Protein-Specific T Cells: J. Chen, et al.; J. Immunol. 167, 1297 (2001)
- Cutting Edge: Induced Indoleamine 2,3 Dioxygenase Expression in Dendritic Cell Subsets Suppresses T Cell Clonal Expansion: A.L. Mellor, et al.; J. Immunol. 171, 1652 (2003)
- Tim-3 inhibits T helper type 1-mediated auto- and alloimmune responses and promotes immunological tolerance: A. Sanchez-Fueyo, et al.; Nat. Immunol. 4, 1093 (2003)
- In Vitro and In Vivo Evaluation of Staphylococcal Superantigen Peptide Antagonists: G. Rajagopalan, et al.; Infect. Immun. v72, 6733 (2004)
- Blocking inducible co-stimulator in the absence of CD28 impairs Th1 and CD25+ regulatory T cells in murine colitis: Y.P. de Jong, et al.; Internat. Immunol. 16, 205 (2004)
- Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase: A.L. Mellor, et al.; Internat. Immunol. 16, 1391 (2004)
- A mutant B7-1/Ig fusion protein that selectively binds to CTLA-4 ameliorates anti-tumor DNA vaccination and counters regulatory T cell activity: R. Chakrabarti, et al.; Vaccine 23, 4553 (2005)
- Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses: M.J. Butte, et al.; Immunity 27, 111 (2007)
- Monovalent antibody scFv fragments selected to modulate T-cell activation by inhibition of CD86–CD28 interaction: R. Kolly, et al.; Prot. Engin. Des. Sel. 20, 91 (2007)
- Pivotal Advance: CTLA-4+ T cells exhibit normal antiviral functions during acute viral infection: H.-P. Raué & M.K. Slifka; J. Leuk. Biol. 81, 1165 (2007)
- Targeted Cleavage of Signaling Proteins by Caspase 3 Inhibits T Cell Receptor Signaling in Anergic T Cells: I. Puga, et al.; Immunity 29, 193 (2008)
- The Tumor Necrosis Factor-Family Receptor DR3 is Essential for Diverse T-Cell Mediated Inflammatory Diseases: F. Meylan, et al.; Immunity 29, 79 (2008)
- Improved immunological tolerance following combination therapy with CTLA-4/Ig and AAV-mediated PD-L1/2 muscle gene transfer: S. Adriouch, et al.; Front. Microbiol. 2, 199 (2011)